Indication
Hypertension,Essential
8 clinical trials
21 products
1 drug
Product
AD-223AProduct
AD-223BProduct
AD-223CClinical trial
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential HypertensionStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential HypertensionStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Product
AD-224AProduct
AD-224CProduct
AD-224BProduct
AD-209Product
AD-2091Clinical trial
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential HypertensionStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive MedicationsStatus: Active (not recruiting), Estimated PCD: 2022-01-31
Product
AlcoholClinical trial
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvascular Function and Vessel Remodeling in Hypertensive HumansStatus: Terminated, Estimated PCD: 2022-08-31
Product
CaptoprilProduct
EnalaprilProduct
HydrochlorothiazideClinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ADX-850 in Participants With HypertensionStatus: Recruiting, Estimated PCD: 2025-12-31
Product
ADX-850Drug
VarlilumabClinical trial
Association of Long-term Use of Calcium Channel Blockers (CCB) and Risk of Breast Cancer: A Retrospective Longitudinal Observational StudyStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Calcium channel blockerProduct
Beta blockerProduct
DiureticProduct
RASProduct
Other AHTProduct
None AHTClinical trial
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled TrialStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Songling Xuemaikang